Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2017, Article ID 6091709, 6 pages
https://doi.org/10.1155/2017/6091709
Research Article

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ

1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
4UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

Correspondence should be addressed to Chelsea Anderson; ude.cnu.liame@93aec

Received 1 March 2017; Accepted 14 August 2017; Published 13 September 2017

Academic Editor: Lance A. Liotta

Copyright © 2017 Chelsea Anderson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar
  2. K. Kerlikowske, “Epidemiology of ductal carcinoma in situ,” Journal of the National Cancer Institute - Monographs, no. 41, pp. 139–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Innos and P. L. Horn-Ross, “Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast,” Breast Cancer Research and Treatment, vol. 111, no. 3, pp. 531–540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 1, 2016.
  5. B. Fisher, J. Dignam, N. Wolmark et al., “Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial,” Lancet, vol. 353, no. 9169, pp. 1993–2000, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Cuzick, I. Sestak, S. E. Pinder et al., “Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial,” The Lancet Oncology, vol. 12, no. 1, pp. 21–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Forbes, I. Sestak, A. Howell et al., “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial,” The Lancet, vol. 387, no. 10021, pp. 866–873, 2016. View at Publisher · View at Google Scholar
  8. R. G. Margolese, R. S. Cecchini, T. B. Julian et al., “Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial,” The Lancet, vol. 387, no. 10021, pp. 849–856, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. T. W. F. Yen, H. M. Kuerer, R. A. Ottesen et al., “Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3251–3258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. H. B. Nichols, E. J. A. Bowles, J. Islam et al., “Tamoxifen initiation after ductal carcinoma in situ,” The Oncologist, vol. 21, no. 2, pp. 134–140, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. M. R. Flanagan, M. H. Rendi, V. K. Gadi, K. E. Calhoun, K. W. Gow, and S. H. Javid, “Adjuvant endocrine therapy in patients with ductal carcinoma in situ: a population-based retrospective analysis from 2005 to 2012 in the national cancer data base,” Annals of Surgical Oncology, vol. 22, no. 10, pp. 3264–3272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. H. S. Feigelson, N. M. Carroll, S. Weinmann et al., “Treatment patterns for ductal carcinoma in situ from 2000–2010 across six integrated health plans,” SpringerPlus, vol. 4, no. 1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Livaudais, E. S. Hwang, L. Karliner et al., “Adjuvant hormonal therapy use among women with ductal carcinoma in situ,” Journal of Women's Health, vol. 21, no. 1, pp. 35–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. L. C. Jackson, F. Camacho, E. A. Levine, R. T. Anderson, and J. H. Stewart IV, “Patterns of care analysis among women with ductal carcinoma in situ in North Carolina,” American Journal of Surgery, vol. 195, no. 2, pp. 164–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Haque, N. S. Achacoso, S. W. Fletcher et al., “Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans,” American Journal of Managed Care, vol. 16, no. 5, pp. 351–360, 2010. View at Google Scholar · View at Scopus
  16. F. Nakhlis, L. Lazarus, N. Hou et al., “Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma,” Journal of the American College of Surgeons, vol. 201, no. 5, pp. 688–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. A. Virnig, M. T. Torchia, S. L. Jarosek, S. Durham, and T. M. Tuttle, Use of Endocrine Therapy following Diagnosis of Ductal Carcinoma In Situ or Early Invasive Breast Cancer: Data Points # 14, Data Points Publication Series, Agency for Healthcare Research and Quality, Rockville, MD, USA, 2011.
  18. C. Anderson, A. M. Meyer, S. B. Wheeler, L. Zhou, K. E. Reeder‐Hayes, and H. B. Nichols, “Endocrine therapy initiation and medical oncologist utilization among women diagnosed with ductal carcinoma in situ,” The Oncologist, vol. 22, no. 5, pp. 535–541, 2017. View at Publisher · View at Google Scholar
  19. D. C. Allred, S. J. Anderson, S. Paik et al., “Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24,” Journal of Clinical Oncology, vol. 30, no. 12, pp. 1268–1273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Zhao, N. Hei, Y. Wu et al., “Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ,” Cancer, vol. 123, no. 6, pp. 940–947, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Cuzick, I. Sestak, J. F. Forbes et al., “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial,” The Lancet, vol. 383, no. 9922, pp. 1041–1048, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. P. E. Goss, J. N. Ingle, and J. E. Ales-Martinez, “Exemestane for breast-cancer prevention in postmenopausal women,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2381–2391, 2011. View at Publisher · View at Google Scholar
  23. M. E. Ropka, J. Keim, and J. T. Philbrick, “Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 3090–3095, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Gail, J. P. Costantino, J. Bryant et al., “Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer,” Journal of the National Cancer Institute, vol. 91, no. 21, pp. 1829–1846, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. A. N. Freedman, B. Yu, M. H. Gail et al., “Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older,” Journal of Clinical Oncology, vol. 29, no. 17, pp. 2327–2333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. N. J. Bundred, “Aromatase inhibitors and bone health,” Current Opinion in Obstetrics and Gynecology, vol. 21, no. 1, pp. 60–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. I. L. Wapnir, J. J. Dignam, and B. Fisher, “Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS,” Journal of the National Cancer Institute, vol. 103, no. 6, pp. 478–488, 2011. View at Publisher · View at Google Scholar